Navigation Links
NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
Date:6/4/2008

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President and Chief Financial Officer is scheduled to present at the Goldman Sachs 29th Annual Global Healthcare Conference at The Ritz Carlton, Laguna Nigel, in Dana Point, CA, on Wednesday, June 11, 2008, at 3:20 p.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

investorrelations@nuvasive.com nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
9. NuVasive Reports First Quarter 2008 Financial Results
10. NuVasive Acquires First Stem Cell Bone Graft Substitute
11. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's ... , Roberta Jordan is a Certified Nurse Midwife who was born and raised ... then went on to complete her masters degree from the University of Mexico. ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology: